A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas
The study is researching an experimental drug called REGN5837 in combination with another
experimental drug, odronextamab. The aim of the study is to see how safe and tolerable the
study drugs are, and to define the recommended dose for phase 2 for the combination.
...
Age: 18 years - 66+
Gender: All
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM
is a type of cancer of the blood. This study will also include participants with
relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).
DLBCL is also a type o...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NH...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab
(EPKINLY™), either by itself or together with other therapies, when treating subjects with
B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify
...
Age: 18 years - 66+
Gender: All
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the efficacy and safety of glofitamab in combination with
gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with
gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Age: 18 years - 66+
Gender: All
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
This phase I trial studies the side effect and best dose of ibrutinib in combination with
rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin
hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive sta...
Age: 18 years - 66+
Gender: All
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the
efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB),
glofitamab, administered by intravenous (IV) infusion as a single agent and in ...
Age: 18 years - 66+
Gender: All